Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:KBH
NYSE:KBHConsumer Durables

How Investors Are Reacting To KB Home (KBH) Weaker Earnings And Cautious 2026 Housing Revenue Guidance

In the first quarter ended February 28, 2026, KB Home reported lower sales and net income year over year, while also completing a US$150 million share repurchase totaling 2,397,196 shares under its October 2025 authorization. At the same time, management issued revenue guidance for the second quarter and full year 2026 that frames housing revenues within a relatively tight range, underscoring a cautious demand outlook despite continued capital returns. Next, we will examine how KB Home’s...
NasdaqGS:FA
NasdaqGS:FAProfessional Services

Share Buyback And Risk Pivot Could Be A Game Changer For First Advantage (FA)

At the March 12, 2026 BofA Securities Information & Business Services Conference, First Advantage Corporation highlighted 17% fourth-quarter revenue growth, a transition toward capital risk management solutions, and board approval of a US$100,000,000 share repurchase program. The company’s emphasis on expanding beyond background screening into a broader capital risk management platform, supported by about 97% client retention, underlines management’s confidence in scaling the business...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status

Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen. See our latest analysis for Relay Therapeutics. The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41%...
NYSE:GLOB
NYSE:GLOBIT

How Investors Are Reacting To Globant (GLOB) Expanding AI From Cancer Drug Discovery To Payments Infrastructure

Recently, Globant and PharmaMar announced a collaboration to apply Globant Enterprise AI in accelerating cancer drug discovery, while Globant and Adyen formalized a global partnership making Globant a lead integration partner for Adyen’s payments platform. Together, these alliances show how Globant is embedding its AI and integration capabilities at the core of critical workflows in both healthcare R&D and global payments infrastructure. Now we’ll examine how Globant’s AI-powered PharmaMar...
BME:ENG
BME:ENGGas Utilities

Assessing Enagás (BME:ENG) Valuation After Supportive Hydrogen Regulation Shift

Regulatory shift puts Enagás (BME:ENG) hydrogen plans in focus New remuneration incentives from the Spanish regulator for Enagás (BME:ENG) hydrogen infrastructure are drawing fresh attention to the stock, after the announcement coincided with a lift in market sentiment around the shares. See our latest analysis for Enagás. That regulatory support for hydrogen comes on top of a 16.41% 7 day share price return and a 28.27% 90 day share price return, while the 1 year total shareholder return of...
OB:KOG
OB:KOGAerospace & Defense

Kongsberg Gruppen (OB:KOG) Valuation Check As Sonar AI Launch Draws Fresh Market Attention

Kongsberg Gruppen (OB:KOG) is back in focus after partner Viam introduced Sonar AI, a virtual sonar operator integrated into Simrad by KONGSBERG fish finding systems, alongside the new SY60 omnidirectional sonar platform. See our latest analysis for Kongsberg Gruppen. The NOK397.8 share price sits against a 4.68% 1 day share price return and a 53.83% 90 day share price return, while the 1 year total shareholder return of 31.31% and very large 5 year total shareholder return suggest momentum...
NYSE:ALLE
NYSE:ALLEBuilding

A Look At Allegion (ALLE) Valuation As Shares Show Softer Recent Returns

With no single headline event driving Allegion (ALLE) into focus, investors are instead looking at the stock's recent performance and fundamentals, including its US$4,067.3m in revenue and US$643.8m in net income. See our latest analysis for Allegion. Allegion’s recent share price performance has been soft, with a 1-month share price return of 10.33% and a year to date share price return of 10.2%. The 1-year total shareholder return sits at 12.27%, which hints at longer term holders faring...
NYSE:SNDR
NYSE:SNDRTransportation

A Look At Schneider National (SNDR) Valuation After Earnings And Guidance Miss Disappoint Investors

Schneider National (SNDR) recently reported quarterly results, with revenue up 4.5% year on year but below analyst expectations, and full-year EPS guidance also under forecasts. This combination has coincided with a 13.5% decline in the share price. See our latest analysis for Schneider National. At a share price of $25.44, Schneider National’s 30 day share price return of 10.36% and 90 day share price return of 5.25% sit against a 1 year total shareholder return of 13.07%. This indicates...
NYSE:GLP
NYSE:GLPOil and Gas

A Look At Global Partners (GLP) Valuation After Recent Share Price Pullback

Global Partners (GLP) has drawn investor attention after its recent share moves, with the stock closing at US$44.37. That price appears alongside mixed recent returns and a value score of 3. See our latest analysis for Global Partners. The recent pullback, with a 1-day share price return of 1.40% decline and a 7-day share price return of 4.42% decline, contrasts with a 90-day share price return of 3.98% and multi year total shareholder returns that remain strongly positive. This points to...
NYSE:KMT
NYSE:KMTMachinery

Assessing Kennametal (KMT) Valuation After EPS Upgrade And Top Analyst Rating Boost

Kennametal (KMT) is back on investors’ radar after its consensus EPS estimate for the current year moved 56.8% higher in the past 3 months, alongside an upgrade to Zacks Rank #1. See our latest analysis for Kennametal. The share price has moved to US$36.08 after a 25.93% 90 day share price return. The 1 year total shareholder return of 74.83% contrasts with a recent 10.43% 1 month share price decline, suggesting that momentum has cooled after a strong run. If this kind of swing in sentiment...
NYSE:SXT
NYSE:SXTChemicals

Sensient’s US$250 Million “Project Prism” Expansion Could Be A Game Changer For Sensient Technologies (SXT)

On March 23, Sensient Food Colors, a division of Sensient Technologies, marked the start of “Project Prism,” a major expansion of its largest natural color plant in St. Louis, Missouri, as part of a planned US$250 million program to grow capacity, supply chain and workforce. This expansion underlines how Sensient is committing significant long-term capital to meet rising demand for natural food colors as brands move away from artificial additives. Next, we’ll examine how Project Prism’s...
NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

What Newmark Group (NMRK)'s Major Suburban Philadelphia Portfolio Win Means For Shareholders

In March 2026, Newmark Group, Inc. was awarded the exclusive leasing, property management and project management assignment for a 66-building, 4.2 million-square-foot office and flex portfolio across key Suburban Philadelphia submarkets including Wayne, Malvern, Exton and Horsham. This large, court-receiver-controlled mandate underscores Newmark’s role in higher-quality, flex-oriented suburban assets where occupancy is comparatively strong and operational improvement is a core focus. Next,...
NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data

Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months. See our latest analysis for Arcellx. Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum...